一项新的基因检测方法可帮助医生确定未知原发部位(CUP)的转移癌。美国Arcturus Bioscience公司研制的智能化检测方法可使医生通过Nichols研究所Quest实验室进行检测评估。尽管CUP的转移癌细胞可分布于人体的各个组织部位,但原发癌的部位却不能通过物理学检查、病理学分析以及其它检测方法来确定。已确诊的新癌症中仅有3%～15%的患者被确定出CUP。统计数据显示,美国每年新确诊的70 000例CUP的癌症患者的预后普遍较差。Quest诊断实验室副主任Joyce G.Schwartz博士报道说,有关原位癌的信息将有助于医生更好地制定诊疗方案;且提早确定原发肿瘤可增加治疗成功的可能性和总的生存率。这种新的检测方法可潜在地帮助医生鉴别39种原发肿瘤部位以及患者预后和采取的治疗手段是否 A new genetic testing method helps physicians identify metastases from unknown primary sites (CUPs). Arcturus Bioscience company developed intelligent detection method allows doctors through the Nichols Institute Quest laboratory testing and evaluation. Although CUP metastases cancer cells can be distributed in various parts of the body, but the site of primary cancer can not be determined by physical examination, pathological analysis and other detection methods. Only 3% to 15% of newly diagnosed cancers have been identified as CUP. Statistics show that the prognosis for 70,000 newly diagnosed CUP cancer patients in the United States is generally poor each year. Dr. Joyce G. Schwartz, associate director of the Quest Diagnostics Laboratory, reports that information on carcinoma in situ will help physicians better define treatment options and that early detection of primary tumors may increase the likelihood of treatment success and overall survival . This new test can potentially help physicians identify 39 primary tumor sites as well as patient outcomes and therapies taken